Literature DB >> 10944

Bioavailability and dissolution of different formulations of oxytetracycline preparations.

A Hart, H E Barber, T N Calvey.   

Abstract

1 The concentration of oxytetracycline in plasma was studied by microbiological assay after oral administration of five different preparations of the antibiotic. None of these preparations had been studied previously. 2 There was a statistically significant correlation between the time required for 50% dissolution at pH 2 and biological availability, as assessed by the peak plasma level or the area under the plasma concentration-time curve. 3 The mean bioavailability of oxytetracycline was greatest with preparations of the hydrochloride, and with film-coated tablets of the dihydrate. In contrast, sugar-coated tablets of oxytetracycline dihydrate were associated with poorer dissolution characteristics and reduced biological availability.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 10944      PMCID: PMC1402579          DOI: 10.1111/j.1365-2125.1975.tb01588.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  5 in total

1.  Biological availability and in vitro release from oral oxytetracycline and tetracycline preparations.

Authors:  T Bergan; B Oydvin; I Lunde
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1973

2.  Cross-over study of ten tetracycline preparations.

Authors:  J Tuomisto; P Männistö
Journal:  Eur J Clin Pharmacol       Date:  1973-06       Impact factor: 2.953

3.  Fluorometric estimation of oxytetracycline in blood and plasma.

Authors:  B Scales; D A Assinder
Journal:  J Pharm Sci       Date:  1973-06       Impact factor: 3.534

4.  Serum levels of tetracycline after different administration forms.

Authors:  A E Altmann; H Beeuwkes; P J Brombacher; H J Buytendijk; A H Gijzen; F P Maesen
Journal:  Clin Chim Acta       Date:  1968-05       Impact factor: 3.786

5.  Therapeutic nonequivalence of oxytetracycline capsules.

Authors:  G W Brice; H F Hammer
Journal:  JAMA       Date:  1969-05-19       Impact factor: 56.272

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.